Form 8-K OTONOMY, INC. For: Aug 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes Needed
August 30, 2017 10:44 AM EDTCowen analyst Ken Cacciatore lowered his price target on Otonomy (NASDAQ: OTIC) to $9.00 (from $55.00) while maintaining an Outperform rating following the Otividex failure.
Cacciatore said said the company will now need to make dramatic and rapid spending reductions and the focus... More
UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX Fails
August 30, 2017 7:33 AM EDT(Updated - August 30, 2017 7:37 AM EDT)
Otonomy (NASDAQ: OTIC) dropped 77% after shares resumed following a brief trading halt pending results for its AVERTS-1 Phase 3 clinical trial of OTIVIDEX in patients with Ménières disease. The clinical trial missed its primary endpoint.
... MoreOtonomy (OTIC) to Resume Trading at 7:30 AM ET
August 30, 2017 7:25 AM EDTOtonomy (NASDAQ: OTIC) to Resume Trading at 7:30 AM ET
... More